Pre-Sleep Creatine Enhances Anaerobic Power in Recreationally Active Females

NCT ID: NCT06937190

Last Updated: 2025-04-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-01

Study Completion Date

2025-07-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a randomized, double-blind, placebo-controlled trial designed to examine the effects of pre-sleep creatine monohydrate supplementation on anaerobic performance and muscle damage markers in recreationally active females. Participants will be randomly assigned to receive either 5 grams of creatine monohydrate or a placebo 30 minutes before sleep for seven consecutive days. Anaerobic performance will be assessed using the Wingate Anaerobic Test, evaluating peak and average power output and fatigue index. Blood samples will be collected before and after the supplementation period to analyze markers of muscle damage, including creatine kinase and lactate dehydrogenase. This study aims to provide insight into the efficacy of short-term, time-specific creatine supplementation for enhancing performance and recovery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anaerobic Performance Sports Nutrition Exercise Recovery Muscle Fatigue Creatine Supplementation Recreational Physical Activity Female Athletes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Participants are randomly assigned to one of two groups: a creatine supplementation group or a placebo group, and they remain in that group for the duration of the trial.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Neither the participants nor the investigators know which intervention the participant is receiving.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Creatine Monohydrate Supplementation

Participants will receive 5 grams of creatine monohydrate powder dissolved in water, flavored with a sugar-free agent, 30 minutes before sleep each night for 7 days.

Group Type EXPERIMENTAL

Creatine Monohydrate

Intervention Type DIETARY_SUPPLEMENT

Participants will receive 5 grams of creatine monohydrate powder dissolved in water, flavored with a sugar-free agent, 30 minutes before sleep each night for 7 days.

Placebo Supplementation

Participants will receive 5 grams of a placebo powder (maltodextrin), visually identical and similarly flavored to the creatine supplement, 30 minutes before sleep each night for 7 days.

Group Type PLACEBO_COMPARATOR

Placebo (Maltodextrin)

Intervention Type DIETARY_SUPPLEMENT

Visually identical placebo (maltodextrin powder, 5 g/day), flavored with a sugar-free agent, dissolved in water and consumed 30 minutes before sleep for 7 consecutive days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Creatine Monohydrate

Participants will receive 5 grams of creatine monohydrate powder dissolved in water, flavored with a sugar-free agent, 30 minutes before sleep each night for 7 days.

Intervention Type DIETARY_SUPPLEMENT

Placebo (Maltodextrin)

Visually identical placebo (maltodextrin powder, 5 g/day), flavored with a sugar-free agent, dissolved in water and consumed 30 minutes before sleep for 7 consecutive days.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Female, aged 18 to 25 years

Recreationally active (engaging in structured resistance training 3-4 times per week for the past 6 months)

Regular menstrual cycles (used for scheduling purposes)

Able and willing to provide informed consent

Agreement to maintain normal diet and training routines throughout the study

Exclusion Criteria

History of musculoskeletal injury affecting lower or upper limbs within the past 6 months

Known allergy or intolerance to creatine or maltodextrin

Use of performance-enhancing substances or supplements within the last 30 days

Use of recovery modalities such as massage, cryotherapy, or compression garments during the study period

Current use of anti-inflammatory medication

Pregnancy or breastfeeding

Inability to comply with study protocol or scheduled assessments
Minimum Eligible Age

18 Years

Maximum Eligible Age

25 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ankara Yildirim Beyazıt University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

caglar soylu

Asisstant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Islamic Azad University, Shabestar Branch

Shabestar, East Azerbaijan Province, Iran

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Iran

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Morteza Jourkesh, PhD

Role: CONTACT

+98 938 278 4093

Caglar Soylu, phD

Role: CONTACT

+90 5078593595

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Morteza Jourkesh, PhD

Role: primary

+98 938 278 4093

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

162593019

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.